Update information

Update information

August 2019: The recommendations in section 1.4 on diagnosing and managing hypertension have been removed because diagnosis, treatment and monitoring of hypertension is broadly the same for people with type 2 diabetes as for other people (see the NICE guideline on hypertension in adults). When a different approach is needed for people with type 2 diabetes, this is specified in the hypertension guideline.

May 2017: Text on sodium–glucose cotransporter 2 (SGLT-2) inhibitors was added to the section on initial drug treatment. The algorithm for blood glucose lowering therapy in adults with type 2 diabetes was also updated to revise footnote b with links to relevant NICE guidance on SGLT-2 inhibitors, and new information on SGLT-2 inhibitors was also added to the box on action to take if metformin is contraindicated or not tolerated.

December 2016: The text following recommendation 1.6.31 and the algorithm for blood glucose lowering therapy in adults with type 2 diabetes were updated to include reference to NICE TA418 on dapagliflozin in triple therapy for treating type 2 diabetes.

July 2016: Recommendation 1.7.17 has been reworded to clarify the role of GPs in referring people for eye screening and also to add information on when this should happen.

December 2015: This guideline updates and replaces NICE guideline CG87 (published May 2009). It also updates and replaces NICE technology appraisal guidance 203 and NICE technology appraisal guidance 248.

Recommendations are marked as [new 2015], [2015], [2009] or [2009, amended 2015]:

  • [new 2015] indicates that the evidence has been reviewed and the recommendation has been added or updated.

  • [2015] indicates that the evidence has been reviewed but no change has been made to the recommended action.

  • [2009] indicates that the evidence has not been reviewed since 2009.

  • [2009, amended 2015] or [2009, amended 2016] indicates that the evidence has not been reviewed since 2009, but either changes have been made to the recommendation wording that change the meaning or NICE has made editorial changes to the original wording to clarify the action to be taken (see below).

We have made some changes without an evidence review:

  • The recommendations on eye damage were made consistent with the current practice of the diabetes eye screening programme.

  • The recommendation on the treatment of gastroparesis was replaced by recommendations from the NICE guideline on type 1 diabetes

These changes are labelled [new 2015].

Minor changes since publication

December 2019: Relationships to the NICE guideline on hypertension were clarified, and a link was added to the decision aid on choice of medicine to control blood glucose. We added a link to the patient decision aid and user guide about taking a second medicine to control blood glucose.

June 2018: Recommendation 1.3.11 was added to provide a link to NICE's advice on bariatric surgery.

January 2018: Footnotes were added with links to MHRA warnings about sodium–glucose cotransporter 2 (SGLT-2) inhibitors.

ISBN: 978-1-4731-1477-7

  • National Institute for Health and Care Excellence (NICE)